RBC Capital Maintains Outperform on Biogen, Raises Price Target to $272

Benzinga · 3d ago
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $256 to $272.